Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436087 | 0.86 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL13436086 | 0.82 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL13461937 | 0.75 | CHRNB2 (0.38) | ALDH1A1 | |
| SCHEMBL13462002 | 0.74 | CHRNB2 (0.35) | ALDH1A1 | |
| SCHEMBL3548175 | 0.72 | F10 (0.49) | — | |
| SCHEMBL13461936 | 0.70 | CHRNB2 (0.34) | — | |
| SCHEMBL24290062 | 0.69 | CHRNB2 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL22633349 | 0.68 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL22633339 | 0.68 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29391713 | 0.68 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049587-A1 | Factor Xa inhibitors | F12, F11, F10 | MEN1 680/4885KMT2A 2600/4885NPC1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.